ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $378,704 | -45.1% | 18,172 | -36.9% | 0.18% | -44.4% |
| Q2 2023 | $689,544 | -34.1% | 28,791 | -48.2% | 0.32% | -63.0% |
| Q1 2023 | $1,045,903 | +16.0% | 55,574 | -1.8% | 0.85% | +59.3% |
| Q4 2022 | $901,359 | +3.4% | 56,618 | +6.2% | 0.54% | +7.4% |
| Q3 2022 | $872,000 | +55.2% | 53,318 | +33.6% | 0.50% | +46.9% |
| Q2 2022 | $562,000 | -32.0% | 39,900 | +17.0% | 0.34% | -35.4% |
| Q1 2022 | $826,000 | +93.0% | 34,116 | +105.6% | 0.52% | +65.1% |
| Q1 2021 | $428,000 | -44.2% | 16,590 | +15.7% | 0.32% | -35.1% |
| Q4 2020 | $767,000 | +49.5% | 14,344 | +15.4% | 0.49% | +31.0% |
| Q3 2020 | $513,000 | +20.4% | 12,429 | +41.3% | 0.37% | +5.9% |
| Q2 2020 | $426,000 | – | 8,794 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |